







































































Risk Analysis for Tracheostomy Dependency in Curatively Treated 
Laryngeal Cancer with Organ Preservation 
 
Lukas Anschuetz1, MD; Miranda Visini1; Mohamed Shelan2, MD; *Olgun Elicin2, MD; 
*Roland Giger, MD1 
 
1 Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern 
University Hospital, University of Bern, 3010 Bern, Switzerland  
2 Department of Radiation Oncology, Inselspital, Bern University Hospital, University 
of Bern, 3010 Bern, Switzerland 
 
*Both last authors contributed equally to this article. 
 
Short running title 
Tracheostomy in Laryngeal Cancer 
 
Conflict of Interest 
The authors declare no conflict of interest. 
 
Corresponding Author 
Lukas Anschuetz, MD 
Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, University 
Hospital and University of Bern, 3010 Bern, Switzerland   
Email: lukas.anschuetz@insel.ch 










Background: A tracheostomy has an enormous negative impact on the patient’s 
quality of life. The aim of this study is to describe risk factors for permanent 
tracheostomies in patients undergoing curative organ-preserving treatment of 
laryngeal cancer.  
Methods: The charts of all patients with laryngeal cancer diagnosed at our tertiary 
referral center were reviewed. Cases receiving a tracheostomy before, during or after 
primary organ-preserving treatment were eligible.  
Results: A total of 87 tracheotomized patients were enrolled in the present study. 
During follow-up 48 patients (55%) required a permanent tracheostomy, whilst 39 
patients (45%) were decannulated. Multivariate analysis revealed primary 
radiotherapy (OR=12.857, p<0.001) and recurrence (OR=25.84, p<0.001). as 
independent factors of permanent tracheostomy.  
Conclusion: This study identifies primary curative RT and tumor relapse as 
independent risk factors of permanent tracheostomy dependency in laryngeal cancer 






Tracheostomy is widely recognized as one of the surgical procedures most feared by 
patients suffering from laryngeal cancer. If necessary, it represents a cumbersome 
consequence of an obstructive laryngeal tumor and/or its treatment. In this context, 
the cause of airway obstruction is usually a bulky tumor, fixed vocal cords or 
sequelae of laryngeal cancer treatment. Although inevitable in acute airway 
compromise, we have to keep in mind that a tracheostomy has an enormous 
negative impact on patients’ quality of life, especially regarding speech and 
swallowing.1  
A recent analysis revealed an overall incidence of tracheostomies in advanced 
laryngeal and hypopharyngeal cancer undergoing chemoradiation (CRT) of 34%.2 
CRT protocols for laryngeal cancer allow the preservation of the organ with good 
locoregional disease control.3,4 Despite this organ preservation strategy, a high 
number of head and neck cancer patients remain dependent on feeding tube and 
tracheostomy.5 Radiotherapy (RT) causes fibrosis and edema, which may lead to an 
impaired laryngeal mobility and airway obstruction, requiring a life-saving 
tracheostomy.  
Risk factors for long-term tracheostomy dependency include a pretreatment 
tracheostomy, subglottic extension of the tumor and salvage neck dissection6. 
Moreover, patients requiring a tracheostomy prior to CRT are subject to a higher 
short-term mortality compared to those without tracheostomy.2 
Regarding the extensive morbidity of chronic tracheostomy as well as its financial 
burden, the knowledge on the long-term evolution of these patients is important, 




The aim of this study is to describe the evolution of tracheostomy dependency in 
patients with curatively intended treatment for laryngeal cancer with organ 
preservation. Furthermore, we describe possible risk factors for permanent 
tracheostomy dependency among already tracheostomized patients during primary 
treatment. 
 
Patients and Methods 
Ethical considerations 
Our institutional and regional review board (Inselspital, University Hospital Bern, 
Bern, Switzerland, KEK-Nr. 117/14) granted approval to perform the present study. 
Formal written informed consent was not required for this type of study. 
 
Retrospective cohort study 
The paper and electronic records of all patients diagnosed and with accomplished 
curatively intended treatment for laryngeal squamous cell carcinoma between 2003 
and 2014 at our tertiary referral center were reviewed. Of those, cases undergoing an 
organ-preserving treatment necessitating a tracheostomy before, during or after 
primary treatment were included. Patients requiring first tracheostomy after 
recurrence and those treated with primary total laryngectomy (TLE) were excluded 
from the present study. Further exclusion criteria were: presence of a concomitant 
malignant tumor, interrupted primary treatment and non-curative situations. A follow-
up of at least 2 years was required. 
Patients’ characteristics, initial tumor classification and localization, features of 
primary treatment, type and time of recurrence and its treatment were assessed. 
Regarding the tracheostomy, the time of initial tracheostomy was divided in three 
groups: acute (pre- and peri-treatment), early (>3 months/<2 years after treatment) 
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and late (>2 years after treatment). Furthermore, the occurrence of emergency 
situations leading to an urgent tracheostomy, versus planned or perioperative 
tracheotomies were differentiated. The situation regarding tracheostomy dependency 
at last follow-up was documented for each patient. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7, statistical significance 
was set for a two-tailed alpha to 0.05. According to the final outcome regarding the 
tracheostomy (permanent or transient), groups were compared by Fisher’s exact test 
for nominal parameters. A multivariate nominal logistic regression analysis was 
performed to assess the impact of different risk factors on tracheotomies to remain 
permanent, including variables with p<0.1 but keeping only variables with p<0.05 for 
the final calculation using backwards elimination. 
 
Results 
A total of 477 patients underwent curatively intended treatment for laryngeal cancer 
at our tertiary reference cancer center from 2001 until 2014. Between diagnosis and 
last follow-up, the incidence of tracheostomy in the CRT group (n=359) was 18.4% 
and 4.2% of tracheostomies remained permanent. In patients treated with partial 
laryngectomy (n=17) or transoral surgery (n=62), the incidence of tracheostomy was 
26.6% (0% permanent). Thirty-nine patients were treated with primary total 
laryngectomy, resulting in permanent tracheostomy. Of the whole cohort (n=477), 87 
patients requiring a tracheostomy before, during or after primary treatment with organ 
preservation were enrolled in the present study. Patients underwent either primary 
RT (n=55, 63.2%), or surgery (n=32, 36.8%) followed in n=22 cases by adjuvant RT. 
Totally 26 patients (29.9%) underwent neck dissection and 37 patients (42.5%) 
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received concomitant chemotherapy to RT (CRT). Initial patient’s characteristics are 
summarized in Table 1. Median follow-up of the 87 tracheostomized patients was 48 
months. 5-years recurrence-free survival, local and loco-regional control rates were 
49%, 58% and 57%, respectively. 
The overall decannulation-rate was 45% (n=39), whilst in 48 patients (55%) the 
tracheostomy remained permanent until last follow-up. A total of 59 (67.8%) patients 
underwent an emergency tracheotomy, while 28 (32.2%) received a planned 
tracheotomy. Forty-four patients (50.6%) needed a tracheostomy before or during 
treatment, whereas 43 patients (49.4%) required tracheostomy more than 3 months 
after the end of the therapy.  
In 15 patients, the tracheostomy remained permanent from primary treatment until 
the end of follow-up. However, nearly all patients without relapse had their 
tracheostomy removed (88%). In contrast, all 43 patients with recurrence ended up 
with a permanent tracheostomy. The longitudinal evolution of these patients is 
summarized in Figure 1. 
Primary definitive RT was applied in 75.8% of the patients, additionally 16 of 21 
(76.2%) operated patients underwent adjuvant RT. Irradiation techniques were: 3.8% 
2D conventional RT, 48.1% 3D conformal and 48.1% IMRT/VMAT, without 
statistically significant effect on the outcome regarding permanent tracheostomy. 
Median total dose was 72 Gy (range: 60-76), applied with 2 Gy per fraction. 
Regarding concomitant systemic treatment, we observed 4.6% of 
induction/neoadjuvant chemotherapy in the whole cohort. Of those treated with RT, 
concomitant systemic treatment was applied in 56.1%. No statistically significant 





Univariate outcome analysis 
The results of the univariate analysis regarding the evolution of tracheostomies are 
summarized in Table 2. The most important risk factors for permanent tracheostomy 
were primary RT (OR=12.857, 95% CI: 3.41 - 48.49, p<0.001), recurrence 
(OR=25.84, 95% CI: 7.938 - 73.87, p<0.001) and emergency tracheostomy due to 
respiratory distress (OR=5.46, 95% CI: 2.17-13.74, p<0.001).  
Moreover, we performed a comparison between the surgical and the RT subgroup in 
our cohort. We observed no significant difference regarding demographic distribution, 
tumor classification or tumor relapse. 
 
Multivariate analysis 
Variables remaining statistically significant as independent predictors of a permanent 
tracheostomy in the multivariate analysis were primary RT (OR=57.04, 95%CI: 5.36-
607.49, p=0.008) and relapse (OR=81.22, 95% CI: 9.95-663.20, p<0.0001). The 
results of the multivariate analysis are summarized in Table 3. 
 
Discussion 
This study identifies possible risk factors for tracheostomies to remain permanent in 
patients with primary curative, organ-preserving treatment for laryngeal carcinoma. A 
tracheostomy represents a brutal stigmatization as well as a severe cut into a 
patient’s quality of life.1 Therefore, the prognosis regarding a potential decannulation 
in the future is crucial to patient’s counseling and may even have an impact on 
further therapeutic decisions. Our study reports a long-term decannulation rate of 
only 45% emphasizing the importance of the questions raised. 
Unexpectedly, the initial tumor and nodal classifications had no impact on the long-
term and durable dependency on a tracheostomy in our cohort. The only surrogate 
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factor regarding the primary tumor characteristics was a higher decannulation rate for 
supraglottic tumors. Similarly, a recent study by Jefferson et al. (2015) identified 
subglottic extension as risk factor for chronic tracheostomy dependency.6 However, 
they analyzed laryngeal and hypopharyngeal tumors together in a cohort of 
exclusively CRT treated patients. In fact, the high decannulation rates for supraglottic 
tumors in our cohort may be explained by the surgically treated patients. In this 
context we have to emphasize, that the distribution of T classifications was not 
different between the surgically treated and the irradiated patients in the present 
study. Of course, T classification and tumor localization are important main factors 
regarding indication for primary tracheostomy, especially in a setting with acute 
respiratory distress. According to our results, these considerations appear to be 
different regarding the long-term evolution of the tracheostomy according.  
The most important risk factor for long-term tracheostomy dependency in our cohort 
was primary RT. Irradiation related tissue toxicity leads to an inflammatory reaction of 
the larynx and surrounding tissues. The abundant fibrous scarring of the larynx 
impedes with its mobility and the concomitant mucosal edema leads to further airway 
obstruction. Finally, chondronecrosis may additionally exacerbate the post-
therapeutic laryngopharyngeal dysfunction.  
Moreover, it has been proposed, that tracheostomy is an adverse prognostic factor 
for the oncological outcome of patients suffering from laryngeal cancer.2,8 However, 
this observation was not confirmed in cases of locoregionally advanced laryngeal 
cancers.6 Our study identifies locoregional relapse as an adverse factor for chronic 
tracheostomy dependency in patients undergoing tracheostomy for the initial 
treatment. This observation is most probably related to the additional required 
treatment in case of tumor persistence or relapse. 
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Considering most probably reduced rates of loco-regional control offered by CRT in 
tracheotomized patients2,8 and the higher risk for permanent tracheostomies 
associated with RT according to our results, the question about the best 
management of these patients is raised. The quest for surgical options while 
preserving the laryngeal function led to the development and validation of partial 
transoral and open surgeries. Langerman et al. (2012) demonstrated, that debulking 
is a safe and effective method in patients with tumor-related airway obstruction.7 No 
patient treated by debulking required long-term tracheostomy and all completed the 
following CRT without need for tracheostomy. Eighty-two percent of the patients were 
able to completely avoid tracheostomy during and after treatment, whilst only two 
patients had late tracheostomy within the first year of completing CRT.7 Similarly, Du 
et al. (2016) presented their experience with tumor debulking as a potential 
alternative to tracheostomy in the management of laryngeal cancer airway 
obstruction.9 As long as intubation (e.g. fiber optic naso-tracheal intubation) is 
achievable, a debulking of the tumor may be reasonable in order to prevent 
tracheostomy. However, we have to take into account that this kind of surgery may 
not be always available in emergency situations. 
With the refinement of the surgical techniques, the functional outcomes of surgery 
may be further improved. Baron and Remacle (2008) showed the advantages of 
transoral endoscopic laser microsurgery (TLM), including less need for tracheostomy 
and nasogastric feeding.10 The work of Silver et al. (2009) established that the results 
of TLM are equivalent to those obtained by conventional conservation surgery, with 
better postoperative function, less morbidity and usually without the need for 
tracheostomy.11 They also pointed out, that with the development of laser surgery, 
the use of emergency tracheostomy became less necessary.11 As our results 
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indicate, patients undergoing emergency tracheostomy have a 5.5-fold (95% CI: 
2.17-13.74) increased risk of remaining tracheostomy-dependent.  
Thomas et al. (2012) performed a systematic review about open conservation partial 
laryngectomy, with statistical pooling of outcomes.12 Although the functional 
outcomes were not reported in a standardized fashion in most studies, the high 
overall tracheostomy decannulation rate of 96.3% - with only two studies reporting a 
decannulation rate <90% - reflects a good functional preservation. The average 
larynx preservation rate came to 90.9%.12 In the same way, Paleri et al. (2011) 
published a systematic review and meta-analysis about the oncologic outcomes of 
open conservation laryngectomy for recurrent laryngeal carcinoma after radiotherapy 
failure.13 The pooled mean decannulation rate in their article was 95.1%.13 Similarly, 
in a study on the advantages of open partial laryngectomy for salvage treatment after 
CRT, the tracheostomy tube was definitively removed in 90% of patients.14 Another 
study reported the use of supracricoid laryngectomy in selected patients. In this case 
series 23 out of 24 patients (95%) were decannulated within a median time of 37 
days.15 
From an oncologic, functional and socio-economic point of view, patients requiring 
tracheostomy during primary curative treatment for laryngeal cancer represent a 
challenging subgroup. As mentioned above, the main result of our study identifies RT 
and tumor relapse as risk factors for tracheostomies to remain permanent. According 
to the literature, alternative options to tracheostomy for airway management are 
available and its feasibility and efficacy are described.7-15 Finally, TLE would remain 
an option for salvage treatment.16 
We also have to consider the results of non-surgical options as reported by the Department 
of Veterans Affairs Laryngeal Cancer Study Group.17 In this trial a new role for chemotherapy 
in patients with advanced laryngeal cancer was hypothesized and the results showed a high 
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rate of laryngeal preservation in patients treated by induction chemotherapy followed by 
definitive RT with similar rates of overall survival as compared to surgery followed by RT.17 
Forastiere et al. (2013) reported after an observation time of 10 years, that the patients group 
treated by RT alone had the worst laryngectomy free survival (17.2%) as compared to the 
CRT (23.5%) and induction chemotherapy followed by CRT (28.9%) arms. Interestingly, 
improved locoregional control and larynx preservation rates for concomitant CRT as 
compared to induction chemotherapy followed by CRT or RT alone were observed.18 
However, induction/neoadjuvant chemotherapy may serve as an in vivo strategy to select 
patients suitable for CRT or TLE in advanced laryngeal cancer.19 The authors report 
promising functional and oncological outcomes in patients selected for CRT after a single 
cycle of induction chemotherapy. This concept allows to identify non-responders to CRT and 
avoids a full course of CRT before surgical salvage. Moreover, no permanent tracheostomies 
were observed in this cohort of patients, when not requiring TLE. 20  
Depending on functional resources for reeducation and comorbidities of every patient 
in question, the decision about the optimal therapy should be taken in an 
interdisciplinary team and in accordance with the patient. In the context of the 
presented literature and according to our results, we may consider offering affected 
patients a more tailored approach. However, this would first need to be prospectively 
validated. 
We acknowledge the limitations of the present study mainly due to its retrospective 
nature and its inherent challenges, for example the vulnerability to the development 
of a selection bias, the possible presence of confounding variables and the fact that 
we can’t determine causation, only association. Besides, our study has an 
asymmetry in terms of group size (surgery vs. RT). On the other hand, the long-term 






This study suggests primary curative RT and tumor relapse as independent adverse 
factors of permanent tracheostomy dependency in laryngeal cancer patients 
undergoing a tracheostomy during or after primary curative organ-preserving 
treatment. Other possible risk factors for permanent tracheostomy are: male gender, 
supraglottic localization and tracheostomy performed for acute respiratory distress. 
These results may play an important role in the development of nomograms for 
tailored treatment strategies for patients at risk to undergo tracheostomy before, 
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Male gender 80 91.9% 33 84.6% 47 97.9% 
Age (years, range) 59.8 41-80 58.3 41-73 60.9 42-80 
 
Initial tumor and treatment characteristics (No. of patients, %) 
Supraglottic 44 50.6% 25 64.1% 19 39.6% 
Glottic 30 34.5% 10 25.6% 20 41.7% 
Subglottic 2 2.3% 1 2.6% 1 2.1% 
Transglottic 11 12.6% 3 7.7% 8 16.6% 
T1 18 20.7% 7 17.9% 11 23.1% 
T2 30 34.5% 15 38.5% 15 31.3% 
T3 27 31.0% 12 30.8% 15 31.3% 
T4 12 13.8% 5 12.8% 7 14.6% 
N0 55 63.2% 22 56.4% 33 68.8% 
N+ 32 36.8% 17 43.6% 15 31.2% 
 TNM Stage I/II 41 47.1% 16 41.0% 25 52.1% 
TNM Stage III/IV 46 52.9% 23 59.0% 23 47.9% 
Surgery 10 11.5% 7 18.0% 3 6.2% 
Radiotherapy 55 63.2% 16 41.0% 39 81.3% 
Multimodal 22 25.4% 16 41.0% 6 12.5% 
ND 26 29.9% 20 51.3% 6 12.5% 
Concomitant CX 37 42.5% 16 41.0% 21 43.8% 
 
Relapse and relapse treatment characteristics (No. of patients, %) 
Relapse 43 49.4% 5 12.8% 38 79.2% 
Local 29 67.4% 2 40.0% 27 71.1% 
Regional 3 7.0% 2 40.0% 1 2.6% 
Loco-regional 9 20.9% 0 0% 9 23.7% 
Metastatic only 2 4.7% 1 20.0% 1 2.6% 
Salvage surgery 24 55.8% 0 0% 24 63.2% 
Salvage Radiotherapy 3 7.0% 2 40.0% 1 2.6% 
Palliation 16 37.2% 3 60.0% 13 34.2% 
 
Tracheostomy characteristics (No. of patients, %) 
Peri-treatment 44 50.6% 24 61.5% 20 41.7% 
Early post-treatment 
(>3 months, <2 years)  
32 36.8% 10 25.6% 22 45.8% 
Late post-treatment  
(>2 years) 
11 12.6% 5 12.9% 6 12.5% 
Urgent (respiratory 
distress) 
59 67.8% 15 38.5% 38 79.2% 
Planned TST 28 32.2% 24 61.5% 10 20.8% 
Permanent TST after 
primary treatment 
15 17.2% 0 0% 15 31.2% 
 Salvage TLE  23 26.4% 0 0% 23 47.9% 
Permanent TST at last 
follow up 
48 55.2% 0 0% 48 100% 
Follow-up (months, 
median) 
48.1  52.3 
 
 43.4  
 
Abbreviations: CX: chemotherapy, ND: neck dissection, SD: standard deviation, TLE: total 
laryngectomy, TST: tracheostomy 
 
Table 1: Patient’s, treatment and tracheostomy characteristics. Data is shown for the 





Variable  No. of transient 
tracheostomies 
No of permanent 
tracheostomies 
p-value 
Gender Male  33 47 
0.042 
Female  6 1 
     
Tumor localization Supraglottic 25 19 0.024 
Glottic 10 20 0.173 
Subglottic 1 1 >0.999 
Transglottic 3 8 0.332 
     
Tumor 
classification 
T1 7 11 0.606 
T2 15 15 0.505 
T3 12 15 >0.999 
T4 5 7 >0.999 
     
Nodal 
classification 
N0 22 33 
0.269 
N+ 17 15 
     
TNM stage Stage I/II 16 25 
0.305 
Stage III/IV 23 23 
     
Therapy Surgery only 7 3 0.059 
Radiotherapy 16 39 <0.001 
Multimodal 16 6 0.003 
Neck dissection 20 6 
<0.001 No neck 
dissection 
19 42 
Chemotherapy 16 21 
0.830 No 
Chemotherapy 23 27 
     
Relapse Relapse 5 38 
<0.001 
No relapse 34 10 
     
Tracheostomy Peri-treatment 24 20 
0.085 
Post-treatment 15 28 
Emergency 15 38 
<0.001 
Planned 24 10 
 
Table 2: Univariate statistical analysis. Comparisons between groups were 






Univariate Multivariate model Backwards elimination 
 
 
OR 95% CI p value OR 95% CI p value OR 95% CI p value 
Gender M/F 0.117 0.01-0.79 0.042       
Stage ≥III 0.64 0.27-1.50 0.305       
Supraglottic 0.367 0.16-0.87 0.024 1.45 0.32–6.66 0.633    




Any RT in 
treatment 
3.281 0.79-13.66 0.103       
Surgery only 0.258 0.06-1.05 0.059       
ND 0.136 0.05-0.38 <0.001 0.19 0.03–1.46 0.112    






5.46 2.17-13.74 <0.001 2.37 0.52–10.7     
 
Abbreviations: ND: neck dissection, RT: radiotherapy, TST: tracheostomy 
 
Table 3: Odds-ratios (OR) for permanent tracheostomy and multivariate linear 
































Long-term evolution of tracheostomies due to laryngeal cancer treated with organ 
preservation. The median follow-up was 48 months. 
 
 
